Dosing considerations and monitoring of low molecular weight heparins and glycoprotein IIb/IIIa antagonists in patients with renal insufficiency

被引：3

作者：

Chidambaram Rammohan

Dan Fintel

机构：

[1] Northwestern University, Feinberg School of Medicine, Division of Cardiology, Chicago, IL 60611-2908

来源：

Current Cardiology Reports | 2003年 / 5卷 / 4期

关键词：

Acute Coronary Syndrome; Renal Insufficiency; Enoxaparin; Abciximab; Unfractionated Heparin;

D O I：

10.1007/s11886-003-0067-3

中图分类号：

学科分类号：

摘要：

Glycoprotein IIb/IIIa inhibitors and low molecular heparins are important new components of the medical treatment for acute coronary syndromes (ACS). Renal insufficiency is a common comorbid condition and high-risk marker for ACS. The safety and efficacy of these treatments in ACS are dependent on the pharmacokinetics of the specific medication. Even though these treatments have been studied in large randomized controlled trials in ACS, there are few prospective data regarding their safety or efficacy in renal insufficiency. Most have been shown to be safe and effective in mild to moderate degrees of renal insufficiency; none have been thoroughly studied in severe renal disease or in patients requiring dialysis therapy. Future prospective trials should include patients with more severe renal insufficiency, as well as combinations of the current recommended therapies. Copyright © 2003 by Current Science Inc.

引用

页码：303 / 309

页数：6

共 28 条

[1]

Braunwald E., Antman E.M., Beasley J.W., ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - Summary article: A report of the American College of Cardiology/American Heart Association task force on practice guidelines, J. Am. Coll. Cardiol., 40, pp. 1366-1374, (2002)

[2]

Lefkovitz J., Plow E.F., Topol E.J., Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine, N. Engl. J. Med., 332, pp. 1553-1559, (1995)

[3]

Herzog C.A., Ma J.Z., Collins A.J., Poor long-term survival after myocardial infarction among patients on long-term dialysis, N. Engl. J. Med., 339, pp. 799-805, (1998)

[4]

Wright K.S., Reeder G.S., Herzog C.A., Et al., Acute myocardial infarction and renal dysfunction: A high-risk combination, Ann. Intern. Med., 137, pp. 563-570, (2002)

[5]

Suwaidi J.A., Reddan D.N., Williams K., Et al., Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes, Circulation, 106, pp. 974-980, (2002)

[6]

Hirsh J., Levin M., Low molecular weight heparin, Blood, 79, pp. 1-17, (1993)

[7]

Cohen M., Demers C., Gurfinkel E.P., Et al., A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease, N. Engl. J. Med., 337, pp. 688-698, (1997)

[8]

Goodman S.G., Cohen M., Bigonzi F., Et al., Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease, J. Am. Coll. Cardiol., 36, pp. 693-698, (2000)

[9]

Antman E.M., McCabe C.H., Gurfinkel E.P., Et al., Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: Results of TIMI11B, Circulation, 100, pp. 1593-1601, (1999)

[10]

Antman E.M., Cohen M., Radley D., Et al., Assessment of the treatment effect of enoxaparin for unstable angina/non Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis, Circulation, 100, pp. 1602-1608, (1999)

← 1 2 3 →